MTOR and cancer: This approach revealed a particularly prominent sensitivity of UCHL1-related cancer cells for DNA-damaging agents (e.g., oxaliplatin, carmustine, irinotecan), HDAC inhibitors (e.g., PCI-34051, ACY-1215, vorinostat), PI3K/AKT/mTOR inhibitors (e.g., GSK2110183, GDC-0068, AZD5363) and tyrosine kinase inhibitors, but a higher resistance for MEK inhibitors (Figure 4G).